Physician profile
Laura Gregory
NPI 1033722970
$2,818.42
in general payments reported to CMS, 2019-2025
14 companies · $1,795 in 2025
The $1,795 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $18.72 · 2024: $1,005 · 2025: $1,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,818.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $838.54 | 2024-2025 | Biktarvy |
| Viiv Healthcare Company | $712.63 | 2024-2025 | Cabenuva, Apretude, Rukobia |
| Astrazeneca Pharmaceuticals LP | $214.92 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $198.13 | 2024-2025 | |
| Lilly USA, LLC | $174.85 | 2024-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $163.08 | 2024-2025 | Pifeltro, Delstrigo, Vaxneuvance |
| Exact Sciences Corporation | $134.68 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $100.89 | 2024-2025 | Krystexxa |
| Novo Nordisk INC | $73.21 | 2025 | Wegovy |
| Cranial Technologies, INC | $70.83 | 2023-2025 | Doc Band |
| Bayer Healthcare Pharmaceuticals INC. | $62.98 | 2024 | |
| Abbvie INC. | $34.87 | 2024-2025 | |
| Seqirus USA INC | $21.05 | 2025 | Flucelvax, Fluad |
| Corcept Therapeutics | $17.76 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.